Jacobs Levy Equity Management’s TRACON Pharmaceuticals, Inc. Common Stock TCON Stock Holding History

Jacobs Levy Equity Management’s Portfolio TCON Stock Details TCON Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-491	Closed	-$62K	–	1061
2018 Q4	$62K	Buy	491 +127	+35%	+$34.5K	﹤0.01%	952
2018 Q3	$149K	Sell	364 -47	-11%	-$21.8K	﹤0.01%	951
2018 Q2	$222K	Sell	411 -346	-46%	-$184K	﹤0.01%	936
2018 Q1	$348K	Buy	757 +323	+74%	+$176K	0.01%	839
2017 Q4	$291K	Buy	+434	New	+$262K	0.01%	850
2017 Q3	–	Sell	-258	Closed	-$124K	–	1028
2017 Q2	$124K	Buy	258 +170	+193%	+$104K	﹤0.01%	885
2017 Q1	$66K	Sell	88 -56	-39%	-$50.2K	﹤0.01%	884
2016 Q4	$141K	Sell	144 -36	-20%	-$41.1K	﹤0.01%	864
2016 Q3	$240K	Sell	180 -6	-3%	-$6.76K	﹤0.01%	860
2016 Q2	$162K	Buy	+186	New	+$246K	﹤0.01%	1045

Other funds holding TCON

PCM

Puissance Capital Management New York $17.3M AUM 149.36% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Telemetry Investments New York $63.3M AUM 0.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

XSC

X-Square Capital Guaynabo, Puerto Rico $297M AUM 32.87% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Jacobs Levy Equity Management's TCON Position: Q1 2019 in Review

Jacobs Levy Equity Management sold out of TRACON Pharmaceuticals, Inc. Common Stock (TCON) in Q1 2019, closing a stake of 491 shares — an estimated $62K sold.

Jacobs Levy Equity Management first reported a position in TCON in Q2 2016 and held it in 10 quarters. The position peaked at $348K in Q1 2018. 24 funds tracked by Wall St. Rank hold TCON as of Q1 2019.

Jacobs Levy Equity Management reported no remaining TRACON Pharmaceuticals, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
Jacobs Levy Equity Management sold 491 TRACON Pharmaceuticals, Inc. Common Stock shares in Q1 2019, an estimated $62K.
Jacobs Levy Equity Management first reported a position in TRACON Pharmaceuticals, Inc. Common Stock in Q2 2016 and held it in 10 quarters.
Jacobs Levy Equity Management's TRACON Pharmaceuticals, Inc. Common Stock position peaked at $348K in Q1 2018.
24 funds tracked by Wall St. Rank held TRACON Pharmaceuticals, Inc. Common Stock as of Q1 2019.

Based on Jacobs Levy Equity Management's 13F filing for Q1 2019, filed 14 May 2019.